CONFERENCE UPDATE: ASCO 2022

Single agent PD-1 blockade as curative-intent treatment in dMMR-LARC

GASTROENTEROLOGY & HEPATOLOGY ONCOLOGY
30 Jul 2022

Glossary: cCR: Clinical complete response; CI: Confidence interval; dMMR: Mismatch repair deficient; ECOG: Eastern Cooperation Oncology Group; FDG: Fluorodeoxyglucose; IV: Intravenous; LARC: Locally advanced rectal cancer; MRI: Magnetic resonance imaging; ORR: Overall response rate; pCR: Pathologic complete response; PD-1: Programmed death 1; PET: Positron emission tomography; PS: Performance status; Q3W: Every 3 weeks; SAEs: Serious adverse events

Get access to our exclusive articles.
Related Articles

Dostarlimab + carboplatin/paclitaxel shows consistent survival benefits in patients with primary advanced/recurrent EC: The BICR outcomes of the RUBY trial

The use of dostarlimab monotherapy has shown to have a durable activity in treating mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) and MMR proficient/microsatellite stable (MMRp/MSS) previously treated endometrial cancer (EC).1 EC associated with dMMR/MSI-H is known as having high levels of tumor mutational burden (TMB) and tumor-infiltrating lymphocytes (TILs), making it more responsive to anti-programmed death-1 (PD-1) therapy monotherapy than MMRp/MSS.1 Additionally, chemotherapy combined with anti-PD-1 treatment has been demonstrated to improve immune system responses and clinical outcomes in various cancer types.1 Therefore, the combination of dostarlimab and chemotherapy could potentially enhance treatment outcomes in the dMMR/MSI-H and overall primary advanced and recurrent EC patient populations compared with chemotherapy alone.1
ONCOLOGY OBSTETRICS & GYNECOLOGY
30 Jul 2023